se gb


Jim Van heusden
Chief Executive Officer

Appointed in 2015.  Born 1971.  PhD.   Jim Van heusden has over 20 years of experience within venture capital, research and development within the pharmaceutical industry, including as Founder and Managing Director at bioskills (2013-2015) and as Partner at the European investment company Gimv (2001-2013). During his appointment at Gimv he also served as a Board member in several biotech companies including Multiplicom NV (as Chairman), Ablynx NV, ActoGeniX NV, Pronota NV and Prosensa. During 1993-2001, Jim Van heusden worked as Senior Scientist at Janssen Pharmaceuticals (Johnson & Johnson). Holdings in Karolinska Development 93,668 shares.



Viktor Drvota
Chief Investment Officer and Deputy Chief Executive Officer

Appointed in 2016. Born 1965 M.D, Ph.D. Associate Prof. In Cardiology. Viktor Drvota has over 13 years of Venture Capital experience with several investements, significant fundraisings, IPOs and exits. He was responsible for Life science at SEB Venture Capital 2002 -2016. During his appointment at SEB VC he also served as a Board member in several biotech and Medtech companies such as Arexis AB, SBL Vaccin AB, Nuevolution AS, Index Pharma AB, Scibase AB, Airsonett AB among others. Before joining SEB in, Dr Drvota worked as Senior Consultant and Associate Professor in Cardiology at the Karolinska Institutet/hospital, Stockholm. Dr Drvota has experience from preclinical as well as clinical research in drug development and medical devices. Dr Drvota has 29 published research articles. Holdings in Karolinska Development0 shares.


Christian Tange
Chief Financial Officer

Appointed in 2014.  Born 1966.  MSc in Economics and Business Administration. Christian Tange has over 15 years’ experience in international growth companies including 12 years within life science as global CFO for CMC Biologics from 2003-2012 and Business Controller for Warner Lambert Nordic from 1997-2000. Christian Tange has also acted as an industrial advisor and consultant for Private Equity Funds and Corporate Finance Advisors in M&A deals within life science.  Other appointments Board member of Dilafor AB and KDev Investments AB. Holdings in Karolinska Development 70,278 shares.


Ulf Richenberg
General Counsel

Appointed in 2008. Born 1955. Master of Laws. Ulf Richenberg has 25 years experience in business law, including positions as legal counsel of KIHAB, Esselte AB and Vattenfall, General Counsel of AB Stokab and Scribona AB and business law consultant at FOI. Other appointments Chairman of KCIF Fund Management AB. Board member of KD Incentive AB. Holdings in Karolinska Development 38,205 shares.


Elisabet Gimbringer

Employed since November 2015. Born 1965. Economics and Business education from Stockholm University. Elisabet has worked as an approved public accountant for 10 years, and as a financial manager, business controller and financial controller for a number of different companies and fields for the last 15 years. Other appointments Board member of KD Incentive AB. No holdings in Karolinska Development.


Eva Montgomerie
Head of Accounting

Employed since october 2013, Employed within the group since 2007. Born 1958. MSc in Business and economics. Eva Montgomerie has worked within the bank and finance sector for 12 years, 10 years within the food and clothing sector and 7 years within life science.  Other appointments Finance manager in Dilafor AB and Pharmanest AB. No holdings in Karolinska Development.


Felicia Rittemar

Employed since 2016. Born 1990. MSc in medical science with a major in Bioentrepreneurship from Karolinska Institutet.